1
|
Paquette M, Phoenix S, Lawson C, Guérin B, Lecomte R, Tai LH, Turcotte ÉE, Leyton JV. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res 2020; 10:69. [PMID: 32592121 PMCID: PMC7334319 DOI: 10.1186/s13550-020-00656-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 06/09/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Nuclear medicine is on the constant search of precision radiopharmaceutical approaches to improve patient management. Although discordant expression of the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) in breast cancer is a known dilemma for appropriate patient management, traditional tumor sampling is often difficult or impractical. While 2-deoxy-2[18F]fluoro-D-glucose (18F-FDG)-positron emission tomography (PET) is an option to detect subclinical metastases, it does not provide phenotype information. Radiolabeled antibodies are able to specifically target expressed cell surface receptors. However, their long circulating half-lives (days) require labeling with long-lived isotopes, such as 89Zr, in order to allow sufficient time for tracer clearance from the blood compartment and to accumulate adequately in target tumors and, thus, generate high-quality PET images. The aim of this study was to develop a dual-tracer PET imaging approach consisting of a fast-clearing small molecule and a slow-clearing antibody. This approach was evaluated in a model consisting of mice harboring separate breast cancer xenografts with either an ER+/HER2- or ER-/HER2+ phenotype, comparable to human metastatic disease with intertumor heterogeneity. Lastly, the aim of our study was to determine the feasibility of specifically identifying these two important phenotypes in an acceptable time window. METHODS Female nude mice were subcutaneously implanted on opposite shoulders with the ER+/HER2- and ER-/HER2+ MCF-7 and JIMT-1 tumor cell lines, respectively. A second model was developed consisting of mice implanted orthotopically with either MCF-7 or JIMT-1 cells. Pharmacokinetic analysis, serial PET imaging, and biodistribution were first performed for [89Zr]Zr-DFO-trastuzumab (89Zr-T) up to 8 days post-injection (p.i.) in JIMT-1 bearing mice. Region-of-interest (ROI) and biodistribution-derived uptake (% injected-activity/gram of tissue [%IA/g]) values and tumor-to-background ratios were obtained. Results were compared in order to validate ROI and identify early time points that provided high contrast tumor images. For the dual-tracer approach, cohorts of tumor-bearing mice were then subjected to sequential tracer PET imaging. On day 1, mice were administered 4-fluoro-11β-methoxy-16α-[18F]-fluoroestradiol (4FMFES) which targets ER and imaged 45 min p.i. This was immediately followed by the injection of 89Zr-T. Mice were then imaged on day 3 or day 7. ROI analysis was performed, and uptake was calculated in tumors and selected healthy organs for all radiotracers. Quality of tumor targeting for all tracers was evaluated by tumor contrast visualization, tumor and normal tissue uptake, and tumor-to-background ratios. RESULTS 89Zr-T provided sufficiently high tumor and low background uptake values that furnished high contrast tumor images by 48 h p.i. For the dual-tracer approach, 4FMFES provided tumor uptake values that were significantly increased in MCF-7 tumors. When 89Zr-T-PET was combined with 18F-4FMFES-PET, the entire dual-tracer sequential-imaging procedure provided specific high-quality contrast images of ER+/HER2- MCF-7 and ER-/HER2+ JIMT-1 tumors for 4FMFES and 89Zr-T, respectively, as short as 72 h from start to finish. CONCLUSIONS This protocol can provide high contrast images of tumors expressing ER or HER2 within 3 days from injection of 4FMFES to final scan of 89Zr-T and, hence, provides a basis for future dual-tracer combinations that include antibodies.
Collapse
Affiliation(s)
- Michel Paquette
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada
| | - Serge Phoenix
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada
| | - Christine Lawson
- Department of Anatomy and Cell Biology, Université de Sherbrooke, Québec, Canada
| | - Brigitte Guérin
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada
- Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada
- Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada
| | - Roger Lecomte
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada
- Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada
- Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada
| | - Lee-Hwa Tai
- Department of Anatomy and Cell Biology, Université de Sherbrooke, Québec, Canada
| | - Éric E Turcotte
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada
- Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada
| | - Jeffrey V Leyton
- Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 3001, 12e Avenue Nord, Sherbrooke (Qc), J1H 5N4, Canada.
- Sherbrooke Molecular Imaging Center, Université de Sherbrooke, Québec, Canada.
- Sherbrooke Pharmacology Institute, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada.
| |
Collapse
|
2
|
Ermert J, Benešová M, Hugenberg V, Gupta V, Spahn I, Pietzsch HJ, Liolios C, Kopka K. Radiopharmaceutical Sciences. Clin Nucl Med 2020. [DOI: 10.1007/978-3-030-39457-8_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
3
|
Paquette M, Lavallée É, Phoenix S, Ouellet R, Senta H, van Lier JE, Guérin B, Lecomte R, Turcotte ÉE. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. J Nucl Med 2017; 59:197-203. [PMID: 28798032 DOI: 10.2967/jnumed.117.194654] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2017] [Accepted: 06/26/2017] [Indexed: 01/13/2023] Open
Abstract
After encouraging preclinical and human dosimetry results for the novel estrogen receptor (ER) PET radiotracer 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol (18F-4FMFES), a phase II clinical trial was initiated to compare the PET imaging diagnostic potential of 18F-4FMFES with that of 16α-18F-fluoroestradiol (18F-FES) in ER-positive (ER+) breast cancer patients. Methods: Patients diagnosed with ER+ breast cancer (n = 31) were recruited for this study, including 6 who underwent mastectomy or axillary node dissection. For each patient, 18F-FES and 18F-4FMFES PET/CT scans were done sequentially (within a week) and in random order. One hour after injection of either radiotracer, a head-to-thigh static scan with a 2-min acquisition per bed position was obtained. Blood samples were taken at different times after injection to assess each tracer metabolism by reverse-phase thin-layer chromatography. The SUVmean of nonspecific tissues and the SUVmax of the tumor were evaluated for each detected lesion, and tumor-to-nonspecific organ ratios were calculated. Results: Blood metabolite analysis 60 min after injection of the tracer showed a 2.5-fold increase in metabolic stability of 18F-4FMFES over 18F-FES. Although for most foci 18F-4FMFES PET had an SUVmax similar to that of 18F-FES PET, tumor contrast improved substantially in all cases. Lower uptake was consistently observed in nonspecific tissues for 18F-4FMFES, notably a 4-fold decrease in blood-pool activity as compared with 18F-FES. Consequently, image quality was considerably improved using 18F-4FMFES, with lower overall background activity. As a result, 18F-4FMFES successfully identified 9 more lesions than 18F-FES. Conclusion: This phase II study with ER+ breast cancer patients showed that 18F-4FMFES PET achieves a lower nonspecific signal and better tumor contrast than 18F-FES PET, resulting in improved diagnostic confidence and lower false-negative diagnoses.
Collapse
Affiliation(s)
- Michel Paquette
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Éric Lavallée
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Serge Phoenix
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - René Ouellet
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Helena Senta
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Johan E van Lier
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Brigitte Guérin
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Roger Lecomte
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| | - Éric E Turcotte
- Sherbrooke Molecular Imaging Center, Research Center of the Sherbrooke University Hospital (CRCHUS), and Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada
| |
Collapse
|
4
|
Kumar S, Verma N, Zubair S, Faisal SM, Kazmi S, Chakraborty S, Owais M, Ahmed N. Design and Synthesis of Novel Nonsteroidal Phytoestrogen-based Probes as Potential Biomarker: Evaluation of Anticancer Activity and Docking Studies. J Heterocycl Chem 2017. [DOI: 10.1002/jhet.2812] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- Sumit Kumar
- Department of Chemistry; Indian Institute of Technology Roorkee; Roorkee 247 667 Uttarakhand India
| | - Nishant Verma
- Department of Chemistry; Indian Institute of Technology Roorkee; Roorkee 247 667 Uttarakhand India
| | - Swaleha Zubair
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh 202002 India
| | - Syed Mohd Faisal
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh 202002 India
| | - Shadab Kazmi
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh 202002 India
| | | | - M. Owais
- Interdisciplinary Biotechnology Unit; Aligarh Muslim University; Aligarh 202002 India
| | - Naseem Ahmed
- Department of Chemistry; Indian Institute of Technology Roorkee; Roorkee 247 667 Uttarakhand India
| |
Collapse
|
5
|
|
6
|
Assessment of the Novel Estrogen Receptor PET Tracer 4-Fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4FMFES) by PET Imaging in a Breast Cancer Murine Model. Mol Imaging Biol 2013; 15:625-32. [DOI: 10.1007/s11307-013-0638-7] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Knott KE, Grätz D, Hübner S, Jüttler S, Zankl C, Müller M. Simplified and automatic one-pot synthesis of 16α-[18F]fluoroestradiol without high-performance liquid chromatography purification. J Labelled Comp Radiopharm 2011. [DOI: 10.1002/jlcr.1916] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- K. E. Knott
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| | - D. Grätz
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| | - S. Hübner
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| | - S. Jüttler
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| | - C. Zankl
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| | - M. Müller
- ABX advanced biochemical compounds GmbH; Heinrich-Glaeser-Str. 10-14; D-01454; Radeberg; Germany
| |
Collapse
|
8
|
Kobayashi H, Longmire MR, Ogawa M, Choyke PL. Rational chemical design of the next generation of molecular imaging probes based on physics and biology: mixing modalities, colors and signals. Chem Soc Rev 2011; 40:4626-48. [PMID: 21607237 PMCID: PMC3417232 DOI: 10.1039/c1cs15077d] [Citation(s) in RCA: 180] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
In recent years, numerous in vivo molecular imaging probes have been developed. As a consequence, much has been published on the design and synthesis of molecular imaging probes focusing on each modality, each type of material, or each target disease. More recently, second generation molecular imaging probes with unique, multi-functional, or multiplexed characteristics have been designed. This critical review focuses on (i) molecular imaging using combinations of modalities and signals that employ the full range of the electromagnetic spectra, (ii) optimized chemical design of molecular imaging probes for in vivo kinetics based on biology and physiology across a range of physical sizes, (iii) practical examples of second generation molecular imaging probes designed to extract complementary data from targets using multiple modalities, color, and comprehensive signals (277 references).
Collapse
Affiliation(s)
- Hisataka Kobayashi
- Molecular Imaging Program, National Cancer Institute/NIH, Bldg. 10, Room B3B69, MSC 1088, 10 Center Dr Bethesda, Maryland 20892-1088, USA.
| | | | | | | |
Collapse
|
9
|
Molecular Imaging in Oncology. Mol Imaging 2009. [DOI: 10.1007/978-3-540-76735-0_15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
10
|
Chemistry of Radiohalogens (F, Br. and I). Mol Imaging 2009. [DOI: 10.1007/978-3-540-76735-0_10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
11
|
Beauregard JM, Croteau É, Ahmed N, van Lier JE, Bénard F. Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11β-Methoxy-16α-18F-Fluoroestradiol Using Serial Whole-Body PET/CT. J Nucl Med 2008; 50:100-7. [DOI: 10.2967/jnumed.108.057000] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Miller P, Long N, Vilar R, Gee A. Synthese von11C-,18F-,15O- und13N-Radiotracern für die Positronenemissionstomographie. Angew Chem Int Ed Engl 2008. [DOI: 10.1002/ange.200800222] [Citation(s) in RCA: 143] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
13
|
Miller P, Long N, Vilar R, Gee A. Synthesis of11C,18F,15O, and13N Radiolabels for Positron Emission Tomography. Angew Chem Int Ed Engl 2008; 47:8998-9033. [DOI: 10.1002/anie.200800222] [Citation(s) in RCA: 726] [Impact Index Per Article: 45.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
14
|
Guha C, Alfieri A, Blaufox MD, Kalnicki S. Tumor biology-guided radiotherapy treatment planning: gross tumor volume versus functional tumor volume. Semin Nucl Med 2008; 38:105-13. [PMID: 18243845 DOI: 10.1053/j.semnuclmed.2007.12.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This issue of Seminars in Nuclear Medicine deals with a watershed event in cancer treatment -- the combined use of functional and anatomical information to guide therapeutic interventions. The use of positron emission tomography/computed tomography (PET/CT) in radiation treatment planning and tumor response evaluation brings a paradigm change in the development of image-guided therapies into routine clinical practice. The implications, as seen in the following articles, are not only promising but also groundbreaking. And, as in every new scientific breakthrough, each step forward generates a myriad of additional important clinical and research questions. Functional imaging takes advantage of the subtle differences between normal and malignant tissues at the cellular level to reveal in vivo unique functional characteristics of neoplasms. The ultimate goal of the partnership between nuclear medicine physicians and radiation oncologists is to use this information with absolute clarity in target definition for radiation treatment planning and therapy, as well as response evaluation. Functional imaging can provide metabolic information and behavioral correlation along with the anatomical imaging for correlative target delineation. Additionally, as a purely diagnostic instrument, PET/CT provides a tool for oncologists to make critical decisions regarding radiation treatment planning modifications secondary to changes in tumor staging (up or down), treatment field modifications, localized control, sites of residual and/or metastatic disease and post therapy response evaluation. The articles in this issue of the seminars provide insights into the current state-of-the-art of functional imaging techniques, mostly centered on the use of (18)F-fluorodeoxyglucose PET/CT in image guided oncologic therapies. Because it is a novel science, the future of image-guided functional treatment planning is bright with technologic and biologic innovations, translational research and new clinical applications.
Collapse
Affiliation(s)
- Chandan Guha
- Department Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA.
| | | | | | | |
Collapse
|
15
|
Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 2008; 37:400-19. [PMID: 17920348 DOI: 10.1053/j.semnuclmed.2007.08.004] [Citation(s) in RCA: 142] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Molecular imaging is the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in a living system. At present, positron emission tomography/computed tomography (PET/CT) is one the most rapidly growing areas of medical imaging, with many applications in the clinical management of patients with cancer. Although [(18)F]fluorodeoxyglucose (FDG)-PET/CT imaging provides high specificity and sensitivity in several kinds of cancer and has many applications, it is important to recognize that FDG is not a "specific" radiotracer for imaging malignant disease. Highly "tumor-specific" and "tumor cell signal-specific" PET radiopharmaceuticals are essential to meet the growing demand of radioisotope-based molecular imaging technology. In the last 15 years, many alternative PET tracers have been proposed and evaluated in preclinical and clinical studies to characterize the tumor biology more appropriately. The potential clinical utility of several (18)F-labeled radiotracers (eg, fluoride, FDOPA, FLT, FMISO, FES, and FCH) is being reviewed by several investigators in this issue. An overview of design and development of (18)F-labeled PET radiopharmaceuticals, radiochemistry, and mechanism(s) of tumor cell uptake and localization of radiotracers are presented here. The approval of clinical indications for FDG-PET in the year 2000 by the Food and Drug Administration, based on a review of literature, was a major breakthrough to the rapid incorporation of PET into nuclear medicine practice, particularly in oncology. Approval of a radiopharmaceutical typically involves submission of a "New Drug Application" by a manufacturer or a company clearly documenting 2 major aspects of the drug: (1) manufacturing of PET drug using current good manufacturing practices and (2) the safety and effectiveness of a drug with specific indications. The potential routine clinical utility of (18)F-labeled PET radiopharmaceuticals depends also on regulatory compliance in addition to documentation of potential safety and efficacy by various investigators.
Collapse
Affiliation(s)
- Shankar Vallabhajosula
- Division of Nuclear Medicine, Department of Radiology,New York Presbyterian Hospital, Cornell University, New York, NY 10021, USA.
| |
Collapse
|